All In Biotech

Drug Trial Radar · NCT06931691

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan on Disease Management, Treatment-Related Outcomes and Healthcare Resource Utilization for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria in China

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jun 10, 2025

Primary completion

Apr 21, 2027

Study completion Apr 21, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 17, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The implementation of new standards for the management of PNH and the use of iptacopan in patients with PNH are expected to change the treatment landscape and improve the overall prognosis of patients. Based on these backgrounds, we plan to conduct a real-world study of iptacopan to further evaluate its impact on treatment-related outcomes, disease management, and healthcare resource utilization in Chinese patients with PNH.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • LNP023Drug

    Capsules for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in hemoglobin (Hb) levels at designated time pointsTime frame: Baseline, 12 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Jinan, China · Recruiting

  • Novartis Investigative Site

    Tianjin, China · Recruiting

  • Novartis Investigative Site

    Tianjin, China · Recruiting

  • Novartis Investigative Site

    Wuhan, China · Recruiting

  • Novartis Investigative Site

    Hefei, Anhui, China · Recruiting

  • Novartis Investigative Site

    Guangzhou, Guangdong, China · Recruiting

  • Novartis Investigative Site

    Guangzhou, Guangdong, China · Recruiting

  • Novartis Investigative Site

    Shijiazhuang, Hebei, China · Recruiting

  • Novartis Investigative Site

    Zhengzhou, Henan, China · Recruiting

  • Novartis Investigative Site

    Zhengzhou, Henan, China · Recruiting

  • Novartis Investigative Site

    Wuhan, Hubei, China · Recruiting

  • Novartis Investigative Site

    Nantong, Jiangsu, China · Recruiting

  • Novartis Investigative Site

    Nanchang, Jiangxi, China · Recruiting

  • Novartis Investigative Site

    Changchun, Jilin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.